This is especially feasible from a therapeutics perspective considering the presence of at least one intact SLC2A1 gene in most Glut1 DS patients, and could be informed by the abundant literature describing molecular pathways that converge onto the Glut1 protein. The gene discussed is SLC2A1; the disease is Dravet syndrome.